Michael Henderson, Apogee Therapeutics CEO
Apogee files to go public, unveiling plans to make a play for Dupixent's turf
Apogee Therapeutics launched last year with $169 million in private financing and is headed for an IPO.
The startup was spun out of Paragon Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
